Share This Author
Human Cannabinoid Pharmacokinetics
- M. Huestis
- Biology, ChemistryChemistry and Biodiversity
- 1 August 2007
The cardiovascular and subjective effects of cannabis are blocked by rimonabant, the first CB-1 cannabinoid-receptor antagonist, documenting thatCB-1 receptors mediate these effects of smoked cannabis in humans.
Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.
Neuropsychological performance in long-term cannabis users.
- H. Pope, A. Gruber, J. I. Hudson, M. Huestis, D. Yurgelun-Todd
- Medicine, PsychologyArchives of General Psychiatry
- 1 October 2001
Some cognitive deficits appear detectable at least 7 days after heavy cannabis use but appear reversible and related to recent cannabis exposure rather than irreversible andrelated to cumulative lifetime use.
Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana.
This study provides the first complete pharmacokinetic profile of the absorption of THC and appearance of metabolites during marijuana smoking, which has implications for understanding the mechanisms underlying the performance-impairing effects of marijuana, as well as for aiding forensic interpretation of cannabinoid blood levels.
Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers
Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in human subjects who chronically smoke cannabis is shown, using positron emission tomography imaging, for the first direct demonstration of cortical cannabinoids CB1 receptor downregulation as a neuroadaptation that may promote cannabis dependence in human brain.
Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: Influence of ionization type, sample preparation, and biofluid
Early-onset cannabis use and cognitive deficits: what is the nature of the association?
Cannabis effects on driving skills.
Evidence suggests recent smoking and/or blood THC concentrations 2-5 ng/mL are associated with substantial driving impairment, particularly in occasional smokers, and future cannabis-and-driving research should emphasize challenging tasks, such as divided attention, and include occasional and chronic daily cannabis smokers.
Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine After Controlled Oral Administration to Young Adults
- Erin A Kolbrich, R. Goodwin, D. Gorelick, R. Hayes, E. Stein, M. Huestis
- MedicineTherapeutic Drug Monitoring
- 1 June 2008
MDMA plasma pharmacokinetic data for the first time from blacks and females as well as measurement of HMMA and HMA concentrations after low and high MDMA doses and more frequent and extended plasma sampling than in prior studies are presented.
Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716.
These findings confirm, for the first time in humans, the central role of CB1 receptors in mediating the effects of marijuana.